Bajaj Healthcare Gears Up for Q2 Reveal on 29th October; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q2 Results
Updated: 16 Oct 2025 • 3:23 pm
Posted by:
Bajaj Healthcare Q2 Results: Bajaj Healthcare, a bulk drug manufacturer serving various pharmaceutical companies, is all set to announce its Q2 results for FY26 on 29th October 2025. Financial analysts anticipate an increase in revenue due to higher sales and significant growth in PAT.
Bajaj Healthcare Q2 Results 2025 Preview
- Bajaj Healthcare's revenue is expected to be in the range of ₹3,304.53 crore to ₹4,568.76 crore, marking a healthy 54.6% to 67.4% YoY increase.
- Profit After Tax, or PAT, is projected to rise by 32.70% YoY or 34.67% QoQ.
- EBITDA of Bajaj Healthcare is expected to decrease by 15.00% YoY to ₹3,456.00 crore.
- Gross Profit is expected to increase by 29.45%(QoQ) and 35.45%(YoY).
Bajaj Healthcare Share Performance
- In the past six months, the share price of Bajaj Healthcare has fallen by 22.76% to reach ₹480.40.
- Moreover, over the past year, the stock has risen by 25.86%.
- Despite this weak short-term performance, Bajaj Healthcare's stock has delivered a financially sound return of 32.15% over the past 5 years.
- As of 16th October 2025, the stock traded at ₹480.35 per share, with a day high of ₹457.76.
Key Factors to Watch for Bajaj Healthcare
- Bajaj Healthcare operates in a highly competitive market, facing pressure from both domestic and international brands.
- The company’s in-house manufacturing capabilities enable better quality control and strategic operations.
- Bajaj Healthcare' performance is mainly linked to the broader economic cycle, and high inflation can reduce demand for its products.
Final Thoughts
Bajaj Healthcare will announce its Q2 FY26 results on 29th October, 2025. Analysts expect strong revenue growth of up to 54.76% YoY, a 32.40% rise in PAT, and a 15.00% increase in EBITDA. Bajaj Healthcare mainly focuses on the new products of this company and EBITDA growth.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2025
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
Recent Articles
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
2 November 2026
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
2 November 2026
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
2 November 2026
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
2 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
TSMC Stock Decoded: Can the Taiwan Chipmaker Reach a $6.5 Trillion Valuation by 2030, Nearly Tripling From Today, and Is It a Buy for the Next Four Years?
EAAA India Alternatives IPO Listing: Shares Debut at 0.63% Premium on NSE and BSE, Check Share Price
ITI Share Price Hits 20% Upper Circuit at Rs 259.14 After Opening Flat: Up 111% in Five Years but Down 34% in a Year, So Is It Time to Book Profits or Hold?
Sebi Backs Removal of LTCG for Foreign Investors, Says Report: What the Proposal Means, Why FPI Outflows Hit Rs 3.04 Lakh Crore in 2026 and What Changes for Indian Investors
Binance Hack Explained: $6.3 Billion Stolen in 20 Minutes, About $3 Billion Frozen, FBI Names North Korea and What It Means for Bitcoin and Indian Crypto Investors
Popular this week
Sensex Options Hit a Record Daily Premium Turnover in October 2026, Up 53% to Rs 35,481 Crore, as Volatility Returned to Indian Markets
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times